BRPI0406749A - Métodos relacionados ao tratamento de distúrbios fincionais do intestino e composição farmacêutica - Google Patents

Métodos relacionados ao tratamento de distúrbios fincionais do intestino e composição farmacêutica

Info

Publication number
BRPI0406749A
BRPI0406749A BR0406749-5A BRPI0406749A BRPI0406749A BR PI0406749 A BRPI0406749 A BR PI0406749A BR PI0406749 A BRPI0406749 A BR PI0406749A BR PI0406749 A BRPI0406749 A BR PI0406749A
Authority
BR
Brazil
Prior art keywords
functional
treatment
present
patient
nari
Prior art date
Application number
BR0406749-5A
Other languages
English (en)
Inventor
Steven B Landau
Original Assignee
Dynogen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynogen Pharmaceuticals Inc filed Critical Dynogen Pharmaceuticals Inc
Publication of BRPI0406749A publication Critical patent/BRPI0406749A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

"MéTODOS RELACIONADOS AO TRATAMENTO DE DISTúRBIOS FUNCIONAIS DO INTESTINO E COMPOSIçãO FARMACêUTICA". A presente invenção refere-se a um método de tratamento de um distúrbio funcional de intestino em um paciente em necessidade do tratamento. O método compreende administrar ao paciente em necessidade do tratamento, uma quantidade terapeuticamente eficaz de um composto que é dotado de atividade de antagonista receptor 5-HT~ 3~ e de atividade inibidora de reabsorção de noradrenalina (NARI). A presente invenção se refere, adicionalmente, a um método de tratamento de um distúrbio funcional de intestino em um paciente que necessite do mesmo, compreendendo co-administrar ao referido paciente, uma primeira quantidade de um antagonista receptor 5-HT~ 3~ e uma segunda quantidade de um NARI, onde as primeira e segunda quantidades compreendem, juntas, uma quantidade terapeuticamente eficaz ou cada uma delas está presente em uma quantidade terapeuticamente eficaz. Ademais, o método da presente invenção compreende a administração do NARI isoladamente. Os distúrbios funcionais do intestino que podem ser tratados de acordo com o método da presente invenção incluem IBS, dilatação abdominal funcional, constipação funcional e diarréia funcional.
BR0406749-5A 2003-01-13 2004-01-13 Métodos relacionados ao tratamento de distúrbios fincionais do intestino e composição farmacêutica BRPI0406749A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44007703P 2003-01-13 2003-01-13
US49248003P 2003-08-04 2003-08-04
PCT/US2004/000807 WO2004062623A2 (en) 2003-01-13 2004-01-13 Method of treating functional bowel disorders

Publications (1)

Publication Number Publication Date
BRPI0406749A true BRPI0406749A (pt) 2005-12-20

Family

ID=32718145

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0406749-5A BRPI0406749A (pt) 2003-01-13 2004-01-13 Métodos relacionados ao tratamento de distúrbios fincionais do intestino e composição farmacêutica

Country Status (13)

Country Link
US (8) US20040147509A1 (pt)
EP (2) EP2286817A3 (pt)
JP (2) JP2006516976A (pt)
KR (1) KR20050111318A (pt)
CN (1) CN100353946C (pt)
AU (1) AU2004204825B2 (pt)
BR (1) BRPI0406749A (pt)
CA (1) CA2512983A1 (pt)
MX (1) MXPA05007381A (pt)
NZ (1) NZ541008A (pt)
PL (1) PL378367A1 (pt)
WO (1) WO2004062623A2 (pt)
ZA (1) ZA200505817B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
AU2004204827B2 (en) * 2003-01-13 2006-06-29 Dynogen Pharmaceuticals, Inc. Method of treating nausea, vomiting, retching or any combination thereof
BRPI0406749A (pt) * 2003-01-13 2005-12-20 Dynogen Pharmaceuticals Inc Métodos relacionados ao tratamento de distúrbios fincionais do intestino e composição farmacêutica
ATE365554T1 (de) * 2003-04-04 2007-07-15 Dynogen Pharmaceuticals Inc Methode zur behandlung von erkrankungen der unteren harnwege
WO2006080385A1 (ja) * 2005-01-28 2006-08-03 Astellas Pharma Inc. 過敏性腸症候群治療薬のスクリーニング方法
WO2006105117A2 (en) * 2005-03-28 2006-10-05 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
WO2007000046A1 (en) * 2005-06-27 2007-01-04 Holburn Biomedical Corporation Methods for diagnosing functional bowel disease
US20070010543A1 (en) * 2005-07-01 2007-01-11 Dynogen Pharmaceuticals, Inc. Compositions and methods for treating gastrointestinal hypomotility and associated disorders
CA2624943A1 (en) * 2005-10-07 2007-04-19 Colocaps Pty Ltd. Preparation for the treatment of diarrhoea
GB0524668D0 (en) * 2005-12-02 2006-01-11 Novartis Ag Organic compounds
KR101300492B1 (ko) * 2005-12-02 2013-09-02 아이로보트 코퍼레이션 커버리지 로봇 이동성
WO2007120445A1 (en) * 2006-03-31 2007-10-25 Dynogen Pharmaceuticals, Inc. SOLUBLE SALTS OF THIENO [2,3-d] PYRIMIDINE DERIVATIVES
TW200838534A (en) * 2007-02-07 2008-10-01 Astellas Pharma Inc Treatment for irritable bowel syndrome
WO2010024306A1 (ja) * 2008-08-28 2010-03-04 アステラス製薬株式会社 過敏性腸症候群の治療方法
EP2744497B1 (en) * 2011-10-18 2016-04-06 Helsinn Healthcare SA Therapeutic combinations of netupitant and palonosetron
JOP20130213B1 (ar) 2012-07-17 2021-08-17 Takeda Pharmaceuticals Co معارضات لمستقبلht3-5
CN104884064A (zh) 2012-12-24 2015-09-02 纽洛佳斯特拉斯公司 用于治疗胃肠道病症的方法
US9844554B2 (en) 2014-06-24 2017-12-19 Neurogastrx, Inc. Prodrugs of metopimazine
CN106795172B (zh) * 2014-09-29 2020-07-28 武田药品工业株式会社 1-(1-甲基-1h-吡唑-4-基)-n-((1r,5s,7s)-9-甲基-3-氧杂-9-氮杂双环[3.3.1]壬-7-基)-1h-吲哚-3-甲酰胺的晶型
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine
WO2022104234A1 (en) * 2020-11-15 2022-05-19 Castor Trevor P Methods for assaying and measuring the efficacy of anti-nausea compounds
CN113412817B (zh) * 2021-05-31 2022-07-12 成都中医药大学附属医院 提高成模率减少死亡率的ibs-d实验动物模型方法

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US659336A (en) * 1900-05-25 1900-10-09 Charles H Booth Pipe-coupling.
JPS60146891A (ja) * 1984-01-05 1985-08-02 Mitsubishi Chem Ind Ltd 〔２，３−ｄ〕チエノピリミジン誘導体およびその塩
GB8701022D0 (en) * 1987-01-19 1987-02-18 Beecham Group Plc Treatment
ES2059491T3 (es) * 1987-06-29 1994-11-16 Duphar Int Res Derivados de indol con anillos condensados.
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5530008A (en) * 1989-04-21 1996-06-25 Sandoz Ltd. Use of 5-HT3 receptor antagonists in treating panic disorders or obsessive compulsive disorders
US5225407A (en) * 1990-02-22 1993-07-06 Glaxo Group Limited 5-HT3 receptor antagonists for the treatment of autism
CA2112487C (en) * 1991-06-26 2003-04-15 James W. Young Method and compositions for treating emesis, nausea and other disorders using optically pure r(+) ondansetron
JP2699794B2 (ja) * 1992-03-12 1998-01-19 三菱化学株式会社 チエノ〔３，２−ｂ〕ピリジン誘導体
US5262428A (en) * 1992-03-13 1993-11-16 Wake Forest University Biologically active tropane derivatives
ATE173159T1 (de) 1992-03-25 1998-11-15 Depomed Systems Inc Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5434174A (en) * 1992-07-17 1995-07-18 Eli Lilly And Company Isoxazole derivatives for the treatment of irritable bowel syndrome
DE4238553A1 (de) * 1992-11-14 1994-05-19 Kali Chemie Pharma Gmbh Neue Imidazol-1-yl-Verbindungen enthaltende Arzneimittel
JPH0616557A (ja) * 1992-12-21 1994-01-25 Mitsubishi Kasei Corp 脳機能障害改善剤
GB9406857D0 (en) * 1994-04-07 1994-06-01 Sandoz Ltd Improvements in or relating to organic compounds
MY113062A (en) * 1994-05-10 2001-11-30 The Wellcome Foundation Ltd Amide derivatives and their therapeutic use
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
MY113429A (en) 1995-02-28 2002-02-28 Univ Temple Controlled release tablet containing swellable polyethylene oxide
EP0827402A2 (en) * 1995-05-17 1998-03-11 Cedars-Sinai Medical Center Compositions containing fatty acids for improving digestion and absorption in the small intestine
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
ATE201021T1 (de) * 1995-07-28 2001-05-15 Dainippon Pharmaceutical Co (r)-5-bromo-n-(1-ethyl-4-methylhexahydro-1h-1,4 diazepin-6-yl)-2-methoxy-6-methylamino-3- pyridincarboxamid, verfahren zu seinerherstellung und dieses enthaltende medizinische zubereitung
AU702594B2 (en) * 1995-10-13 1999-02-25 Duphar International Research B.V. Process for the preparation of enantiomerically pure imidazolyl compounds
ES2208870T3 (es) * 1996-02-15 2004-06-16 Janssen Pharmaceutica N.V. Uso de antagonistas del receptor 5ht4 para resolver los efectos gastrointestinales de los inhibidores de la reabsorcion de serotonina.
WO1997047285A1 (en) 1996-06-10 1997-12-18 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
SE9701304D0 (sv) * 1997-04-09 1997-04-09 Astra Pharma Prod Compounds
DK0975327T3 (da) * 1997-04-18 2003-10-20 Janssen Pharmaceutica Nv Anvendelse af 5HT3-antagonister til befordring af tarmudskylning
US6177879B1 (en) * 1997-05-09 2001-01-23 Honda Giken Kogyo Kabushiki Kaisha Battery rental system and apparatus
ES2248908T7 (es) 1997-06-06 2014-11-24 Depomed, Inc. Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
DE19813661A1 (de) * 1997-08-01 1999-02-04 Solvay Pharm Gmbh Gegen Racemisierung stabilisierte pharmazeutische Zubereitungen von Cilansetron
DE19734444A1 (de) * 1997-08-08 1999-02-11 Basf Ag 3-Substituierte 3,4,5,7-Tetrahydro-pyrrolo(3',4':4,5) thieno (2,3-d) pyrimidin-Derivate, ihre Herstellung und Verwendung
US6156771A (en) * 1997-08-28 2000-12-05 Rubin; Walter Method for alleviation of lower gastrointestinal disorders in a human patient
US6054461A (en) * 1997-09-16 2000-04-25 Solvay Pharmaceuticals Gmbh Treatment of neuropathic pain
US6117879A (en) * 1997-09-16 2000-09-12 Solvay Pharmaceuticals Gmbh Methods of using moxonidine to inhibit nociceptive pain
GB9721139D0 (en) * 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments
US6211171B1 (en) * 1998-05-19 2001-04-03 Dalhousie University Use of antidepressants for local analgesia
US6456458B1 (en) * 1998-08-08 2002-09-24 Nidec Corporation Disk-drive motor rotating on a magnetically counterbalanced single hydrodynamic thrust bearing
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
AU2672500A (en) * 1999-02-18 2000-09-04 Novartis Ag Systemic use of 5-ht3 receptor antagonists against rheumatic inflammatory processes
DE60042446D1 (de) * 1999-02-18 2009-08-06 Novasearch Ag Verwendung von antagonisten der 5-ht3-rezeptoren zur behandlung von muskuloeskeletalen erkrankungen
US6362202B1 (en) * 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6353005B1 (en) * 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
US6194382B1 (en) * 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
DE19911371A1 (de) * 1999-03-15 2000-09-21 Solvay Pharm Gmbh Arzneimittel zur Behandlung von funktionellen Störungen und Erkrankungen der unteren Darmwege, insbesondere von damit einhergehenden abdominalen visceralen Schmerzen
US6448962B1 (en) 1999-05-14 2002-09-10 Three-Five Systems, Inc. Safety timer to protect a display from fault conditions
DE19929197A1 (de) * 1999-06-25 2000-12-28 Novosis Pharma Ag Transdermalsysteme zur Abgabe von 5-HT3-Rezeptor-Antagonisten und ihre Verwendung zur antiemitischen Behandlung
ES2246488T3 (es) * 1999-07-01 2006-02-16 PHARMACIA & UPJOHN COMPANY LLC Reboxetina para tratar la migraña.
GB2355191A (en) * 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
NZ518739A (en) 1999-11-02 2004-12-24 Depomed Inc Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
PT1251832E (pt) 2000-02-04 2007-01-31 Depomed Inc Forma de dosagem constituída por invólucro-e-núcleo que conduz a uma libertação do fármaco de ordem zero
JP2001243182A (ja) 2000-02-29 2001-09-07 Nec Corp サーバシステム及びＷｅｂコンテンツとサーバシステムとの連動方法
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6566369B2 (en) * 2000-07-26 2003-05-20 Solvay Pharmaceuticals Gmbh Medicament containing cilansetron for the treatment of non-obstipative male irritable bowel syndrome patients
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
US6588708B2 (en) * 2001-01-29 2003-07-08 The Boeing Company Spacecraft methods and structures for acquiring and determining power-safe attitudes
US20020107244A1 (en) * 2001-02-02 2002-08-08 Howard Harry R. Combination treatment for depression
GB0112494D0 (en) * 2001-05-22 2001-07-11 Arachnova Therapeutics Ltd New therapeutic use
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
US20030031711A1 (en) 2001-05-29 2003-02-13 Fara John W. Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
US6568519B2 (en) 2001-08-10 2003-05-27 Borgwarner, Inc. Torque limiting chain sprocket assembly
US6475078B1 (en) * 2001-10-09 2002-11-05 Norb Borcherding Air ventilating device
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US6458795B1 (en) * 2001-11-15 2002-10-01 University Of Florida Method and composition for treatment of irritable bowel disease
US6770655B2 (en) * 2002-01-18 2004-08-03 Aryx Therapeutics 5-HT3 receptor antagonists and methods of use
GB0202265D0 (en) * 2002-01-31 2002-03-20 Arachnova Therapeutics Ltd New therapeutic use
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
CA2479350A1 (en) * 2002-03-15 2003-09-25 Cypress Bioscience, Inc. Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
US20040032780A1 (en) * 2002-04-08 2004-02-19 Ehud Langberg System and method for generating a clock signal in a communication system
AU2003255712B2 (en) * 2002-07-10 2007-03-15 Arachnova Therapeutics Ltd. 4-(2-fluorophenyl)-6-methyl-2(1-piperazinyl)thieno(2,3-D) pyrimidine in the treatment of functional bowel disorder
JP2006500427A (ja) * 2002-08-29 2006-01-05 アラクノーバ・セラピューティックス・リミテッド （４−（２−フルオロフェニル）−６−メチル−２−（１−ピペラジニル）チエノ［２，３−ｄ］ピリミジンの新規治療的使用
BRPI0406749A (pt) * 2003-01-13 2005-12-20 Dynogen Pharmaceuticals Inc Métodos relacionados ao tratamento de distúrbios fincionais do intestino e composição farmacêutica
AU2004204827B2 (en) * 2003-01-13 2006-06-29 Dynogen Pharmaceuticals, Inc. Method of treating nausea, vomiting, retching or any combination thereof

Also Published As

Publication number Publication date
CN100353946C (zh) 2007-12-12
US20050032780A1 (en) 2005-02-10
JP2011157372A (ja) 2011-08-18
US20040147509A1 (en) 2004-07-29
US20040254169A1 (en) 2004-12-16
US20050192270A1 (en) 2005-09-01
MXPA05007381A (es) 2006-02-10
PL378367A1 (pl) 2006-04-03
NZ541008A (en) 2007-09-28
AU2004204825B2 (en) 2007-07-19
US20040254170A1 (en) 2004-12-16
WO2004062623A2 (en) 2004-07-29
KR20050111318A (ko) 2005-11-24
US20040259862A1 (en) 2004-12-23
ZA200505817B (en) 2006-04-26
AU2004204825A1 (en) 2004-07-29
CA2512983A1 (en) 2004-07-29
EP2286817A3 (en) 2011-06-15
US20060217391A1 (en) 2006-09-28
EP2286817A2 (en) 2011-02-23
EP1558081A2 (en) 2005-08-03
EP1558081A4 (en) 2006-06-14
WO2004062623A3 (en) 2005-06-09
JP2006516976A (ja) 2006-07-13
US20040254168A1 (en) 2004-12-16
CN1750759A (zh) 2006-03-22

Similar Documents

Publication Publication Date Title
Bassari et al. Jaundice associated pruritis: a review of pathophysiology and treatment
MA29326B1 (fr) Combinaison de composes organiques
Jongen et al. Neuropathic pain and pharmacological treatment
Summey Jr et al. Pharmacologic advances in the systemic treatment of itch
EP2331095A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
Tupal et al. Serotonin 5-HT4 receptors play a critical role in the action of fenfluramine to block seizure-induced sudden death in a mouse model of SUDEP
BRPI0410273A (pt) métodos de tratamento de aterosclerose e de aumento dos nìveis de hdl no soro em um paciente humano em necessidade de tal tratamento, e, composição farmacêutica
BRPI0622054B8 (pt) composto e composição farmacêutica
DE602006021444D1 (de) Therapie zur behandlung der überaktiven blase
EP1539234A4 (en) METHOD FOR PREVENTING OR TREATING CELL MALIGNITY BY ADMINISTERING CD2 ANTAGONISTS
EA200501496A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
EA200400982A1 (ru) Способы лечения пациентов, страдающих от нарушения движений
BR0112661A (pt) Nova combinação de agonista (5ht2) e antagonista (5ht6) da serotonina como formulação farmacêutica
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
SI1735278T1 (sl) Agenti histamin h receptorja priprava in terapevtska uporaba
BRPI0519124A2 (pt) composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇço
BR0012175A (pt) Antagonistas de receptor de igiur5, seletivos para o tratamento de enxaqueca
Thurmond et al. Peripheral neuronal mechanism of itch: histamine and itch
EP2286817A3 (en) Method of treating functional bowel disorders
Thase et al. Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder
Lauerma Successful treatment of citalopram‐induced anorgasmia by cyproheptadine
BRPI0411608A (pt) derivado de 8-aza-biciclo [3.2.1] octano, composição farmacêutica, uso do composto, e, método de tratamento, prevenção ou alìvio de uma doença, um distúrbio ou uma condição de um organismo animal vivo
MX2023000610A (es) Inhibidor de trpv4 como agente terapeutico para enfermedades oculares.
BR0111982A (pt) Tratamento com apomorfina, de disfunção sexual induzida por droga anti depressão
WO2011022633A3 (en) Method of threating cancer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.